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types. Activation of this receptor by extracellular adenosine 5’-triphosphate results in numerous 
downstream events including the release of pro-inflammatory mediators, cell proliferation or death, and 
killing of intracellular pathogens. As a result, P2X7 plays important roles in inflammation, immunity, bone 
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acids in length, however splice isoforms that can alter receptor expression and function, and modify the 
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function varies between human individuals due to numerous single nucleotide polymorphisms resulting in 
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Abstract: The human P2X7 receptor is a trimeric ligand-gated cation channel coded by the P2RX7 
gene located at chromosome position 12q24. P2X7 is expressed in a wide variety of normal and 
disease-associated cell types. Activation of this receptor by extracellular adenosine 5’-triphosphate 
results in numerous downstream events including the release of pro-inflammatory mediators, cell 
proliferation or death, and killing of intracellular pathogens. As a result, P2X7 plays important roles 
in inflammation, immunity, bone homeostasis, neurological function and neoplasia. The P2RX7 
gene encodes a P2X7 subunit 595 amino acids in length, however splice isoforms that can alter 
receptor expression and function, and modify the signaling properties downstream of receptor 
activation also exist. Moreover, the relative amount of P2X7 function varies between human 
individuals due to numerous single nucleotide polymorphisms resulting in either loss- or gain-of-
function. Combinations of these polymorphisms give rise to various haplotypes that can also 
modify P2X7 function. Collectively, P2X7, and its splice and polymorphic variants are attracting 
considerable interest in relation to human health and disease, including the development and 




Extracellular nucleotides and nucleosides operate through a complex network of purinergic 
signaling cascades involving various membrane receptors and ectoenzymes [1, 2]. One member of 
this network is the P2X7 receptor, a trimeric ligand-gated cation channel encoded by the P2RX7 
gene (purinergic receptor P2X, ligand-gated ion channel 7) and belonging to the P2X receptor 
family [3, 4]. Activation of P2X7 by extracellular adenosine 5’-triphosphate (ATP) causes the 
movement of Ca2+, Na+ and K+ across the plasma membrane, as well as the uptake of organic 
cations including fluorescent dyes [3, 4]. P2X7 activation induces an array of downstream events, in 
a cell specific manner, including the release of pro-inflammatory mediators [5], cell proliferation or 
death [6], and killing of intracellular pathogens [7]. P2X7 is predominately expressed on cells of the 
hematopoietic, epithelial, mesenchymal and neural lineages [8]. Subsequently P2X7 plays 
important roles in inflammation, immunity, bone homeostasis, neurological function (including 
pain) and neoplasia. Moreover, the relative amount of P2X7 expression and/or function varies 
between human individuals, which can be explained in part by splice and polymorphic variants. Of 
note, a number of these variants have been associated with diseases. This review will summarize the 
biology of P2X7 including splice and polymorphic P2X7 variants, and detail recent patents relating 
to DNA and gene sequences of P2RX7. Recent patents relating to P2X7 antagonists and their 
relevance to human health and disease have been discussed elsewhere [9, 10]. 
 
THE P2X7 RECEPTOR 
 
The P2X7 receptor is a trimeric ATP-gated cation channel comprised of homomeric 
subunits 595 amino acids in length [11]. Each subunit comprises intracellular amino and carboxyl 
termini with two hydrophobic transmembrane domains, separated by a long glycosylated 
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extracellular loop containing ATP-binding sites [12, 13]. These observations are supported by 
atomic computing modeling of the human P2X7 receptor [14], based on a crystal structure of the 
zebrafish P2X4 receptor [15]. P2X7 subunits may also combine with P2X4 subunits to form 
heteromeric receptors [16], however homomeric P2X7 receptors appear to be the dominant subtype 
in most cell types [11, 17]. 
P2X7 was originally thought to be restricted to cells of the hematopoietic lineages, however 
it is now evident that P2X7 is also present in other cell lineages. In regards to hematopoietic 
lineages in humans, P2X7 is present (in decreasing amounts) on macrophages, dendritic cells, 
monocytes, natural killer cells, B-lymphocytes, T-lymphocytes and erythrocytes [18-21]. P2X7 is 
also present on human mast cells [22], microglia [23], osteoclasts [24], and eosinophils [25]. The 
relative amounts of this receptor, however, in these latter cell types in relation to other human 
hematopoietic cell types remain unknown. Despite the presence of P2X7 on eosinophils, human 
neutrophils appear to be devoid of P2X7 [26, 27]. P2X7 is also present on other human cell types 
including osteoblasts [28], fibroblasts [29], endothelial cells [30], and epithelial cells residing in 
various tissues including the skin, cervix, pancreas and colon (see [31, 32] and references therein). 
Moreover, P2X7 is present on various neural cell types including astrocytes, oligodendrocytes, 
Schwann cells and neurons, however its precise localization and expression in the latter remains 
controversial (see [33, 34] and references therein). Finally, P2X7 is present in various neoplastic 
cells particularly those arising from hematopoietic and epithelial lineages (see [35, 36] and 
references therein). 
P2X7 activation induces a number of well-established downstream signaling events in 
various human cell types (Fig. 1), many of which were originally established or have been 
supported by studies in animal models. The best described signaling event downstream of P2X7 
activation is the activation of the NALP3 inflammasome resulting in the functional maturation and 
release of the pro-inflammatory cytokines, interleukin (IL)-1β and IL-18 from human myeloid cells 
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(reviewed by [37]). Depending on the cell type, environmental conditions and concentration of 
extracellular ATP, P2X7 activation can also promote cell proliferation or induce cell death via a 
number of different intracellular pathways (reviewed by [6]). Moreover, P2X7 activation can 
induce phagosome-lysosome fusion resulting in the killing of intracellular mycobacteria, chlamydia 
and toxoplasma residing with human macrophages (reviewed by [7]). P2X7 activation can also 
induce the release of CD21 (complement component receptor 2), CD23 (low affinity IgE receptor), 
CD62L (L-selectin), matrix metalloproteinase 9 (gelatinase B) and cathepsins from lymphoid and 
myeloid [18, 20, 38-43]; however the mechanisms linking P2X7 to these processes remain poorly 
defined. Finally, P2X7 activation can induce other downstream signaling events in cells of various 
lineages including rapid and reversible phosphatidylserine exposure, membrane blebbing, release of 
microparticles and exosomes, and multinucleated cell formation (reviewed by [44]), as well as the 
formation of reactive oxygen and nitrogen species (reviewed by [45]). 
 
THE HUMAN P2RX7 GENE 
 
The human P2RX7 gene comprises 13 exons and is located at chromosome position 12q24 
[46], a region associated with inflammatory and psychiatric disorders [47, 48]. Initially, a putative 
1.8-kb promoter region upstream of exon 1 was proposed [49], however experimental evidence 
supporting this has been lacking. More recently, the transcription initiation site and an active 
promoter region have been located 91 nucleotides, and 249 to 59 nucleotides respectively upstream 
of exon 1 [50]. Furthermore, target sites for the microRNAs, miR-150 and miR-186 have been 
identified within the P2RX7 3'-untranslated region, which can negatively regulate P2X7 mRNA 
translation or P2X7 expression [51]. Putative microRNA binding sites within the P2RX7 3'-
untranslated region have also been found for miR-625, miR-1275, miR-491-5p and miR-1302 [52], 
but direct evidence in relation to P2X7 expression is lacking. P2RX7 gene expression may also be 
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modulated by other mechanisms including cis-enhancement and hypermethylation as reviewed 
elsewhere [32]. 
 
P2X7 SPLICE ISOFORMS 
 
A number of splice isoforms of the human P2X7 receptor have been identified (Fig. 2). 
Initially, seven variants of human P2X7, resulting from alternative splicing, were identified [53]. 
These were designated as P2X7B to P2X7H by the investigators, with the original, full-length 
receptor encoding 595 amino acids [12] defined as P2X7A. P2X7B includes the intron between 
exons 10 and 11 leading to a new stop codon and a truncated protein lacking the last 171 amino 
acids of the full-length protein, but containing an alternate 18 amino acids following the second 
transmembrane domain. P2X7C to P2X7F lack various exons coding the parts of the extracellular 
domain (exons 4, 5, 7 and 8, and 4 and 8 respectively); P2X7C and P2X7E also contain the same 
intron between exons 10 and 11 as P2X7B. P2X7G and P2X7H contain an additional exon (termed 
exon N3) in the intron between exons 2 and 3, which introduces a new start codon potentially 
leading to translation of a P2X7 protein lacking the first transmembrane domain. P2X7G also 
contains the same intron between exons 10 and 11 as P2X7B, P2X7C and P2X7E. Thus, four of the 
seven splice isoforms of P2X7 have an alternate short carboxyl terminus, while two potentially lack 
the first transmembrane domain. 
Of the above P2X7 variants, two (P2X7B and P2X7H) have been studied in greater detail. 
P2X7B shares a similar tissue distribution to the full-length receptor (P2X7A), with P2X7B mRNA 
expressed at comparable or greater amounts than P2X7A mRNA [53, 54]. The relative distribution 
and amounts of these P2X7 isoforms however, are yet to be compared at the protein level. 
Functional comparisons to P2X7A, demonstrated that P2X7B can form functional channels but not 
pores, and is a poor inducer of caspase-3 and -7 activation [53, 54]. Co-expression of P2X7B with 
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P2X7A however, results in heteromeric receptors that increase the intracellular ATP content and 
endoplasmic reticulum Ca2+ content to activate NFATc1 and stimulate cell growth [54]. 
Collectively, these studies suggest that P2X7A and P2X7B have growth promoting activities, and 
that P2X7A has additional roles in inflammation and cell death [54]. In contrast to P2X7A and 
P2X7B, P2X7H is present at low amounts in tissues, and appears to be non-functional [53]. Despite 
this progress, the specific relevance of these P2X7 splice isoforms to human health and disease 
remains to be defined. 
Three additional P2X7 variants have also been described. A ninth P2X7 variant was named 
P2X7I [55], and results from a rare point mutation (rs35933842; g151+1>t) in the intron between 
exons 1 and 2, leading to a null allele [56]. The significance of this null allele to human health and 
disease is unknown. However, ATP-induced killing of mycobacteria is completely ablated in 
macrophages from subjects heterozygous for both rs35933842 and a second loss-of-function P2RX7 
allele (rs3751143; Glu496Ala) supporting a possible role for P2X7I in increased susceptibility to 
tuberculosis. A tenth variant, P2X7J, has been described [55]. This P2X7 variant lacks exon 8 
resulting in a truncated protein comprising 258 amino acids including an alternate 10 amino acids at 
the C-terminus. P2X7J is non-functional, and when co-expressed with P2X7A results in the 
formation of non-functional P2X7A/P2X7J heteromeric receptors. P2X7J is present in both normal 
and malignant cervical tissue, with higher expression in the latter and leading to the suggestion that 
this variant may protect malignant cells from ATP-induced apoptosis. Finally, an eleventh splice 
variant, P2X7K, has been found in rodents resulting from an additional exon (termed exon 1’) in the 
intron between exons 1 and 2, and leading to a receptor with an alternate N-terminus and first 
transmembrane domain, with increased agonist sensitivity and propensity to form P2X7 pores [57]. 




P2X7 SINGLE NUCLEOTIDE POLYMORPHISMS 
 
A recent survey of the NCBI single nucleotide polymorphism (SNP) database 
(http://www.ncbi.nlm.nih.gov/sites/entrez) has revealed that over 686 SNPs reside within the 
human P2RX7 gene [58]. The majority of these SNPs however are intronic or synonymous. There 
are 28 non-synonymous SNPs, of which only 16 have been characterized for phenotype (Table 1; 
Fig. 3). Of these 16 SNPs, the loss-of-function P2RX7 SNP, rs3751143 (Glu496Ala) [59], has been 
the most extensively studied (Table 2). As seen in Table 2, this SNP impairs a number of P2X7-
mediated processes in a variety of cell types. Although direct evidence is limited, it is likely that 
similar functional defects may also occur for other loss-of-function P2RX7 SNPs. In this regard, 
rs35933842 (g151+1>t), rs28360457 (Arg307Gln), rs2230911 (Thr357Ser) and rs1653624 
(Ile568Asn) also impair ATP-induced apoptosis of macrophages and/or killing of intracellular 
mycobacteria or toxoplasma [60-62]. Conversely, gain-of-function SNPs, rs208294 (His155Tyr), 
rs7958311 (His270Arg) and rs1718119 (Ala348Thr), have been associated with increased ATP-
induced IL-1β release from monocytes [63]. In contrast to most SNPs however, rs3751143 appears 
unique in that the amino acid substitution impairs P2X7-mediated organic cation uptake (pore 
function), but not P2X7-mediated currents (channel function) [64]. This observation has been 
recently challenged [14], however we have argued [65] that the weight of experimental evidence 
still favors the earlier observation [64]. 
Despite the phenotypic characterization of a number of P2RX7 SNPs, the mechanisms by 
which the amino acid substitutions lead to altered function remain poorly understood. Amino acid 
substitutions in the extracellular loop are proposed to alter ATP binding [14, 66, 67]. Consistent 
with this hypothesis, rs28360457 codes for an amino acid substitution (Arg307Gln) [67] at a site 
homologous to the putative ATP-binding sites in other P2X receptors [68]. Amino acid 
substitutions in the transmembrane and C-terminus regions are thought to alter the gating properties 
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of the channel and/or to disrupt channel or pore formation [59, 62, 63], although some evidence 
exists that changes in the C-terminus can also alter ATP sensitivity [14]. In contrast, rs1653624 
codes for an amino acid substitution (Ile568Asn) that prevents trafficking of P2X7 to the plasma 
membrane and leads to a complete loss-of-function when present in homozygous dosage [69]. 
 
P2X7 SINGLE NUCLEOTIDE POLYMORPHISMS & DISEASE 
 
P2RX7 SNPs have been associated with various diseases (Table 3). Of these, the association 
of rs3751143 with increased susceptibility to tuberculosis is the most robust. Of the 10 cohorts 
reported, 6 of these (from various racial groups) have found an increased frequency of the mutant 
allele in this disease (see Table 3). Moreover, this association of rs3751143 with tuberculosis is 
supported by meta-analysis [70]. The increased susceptibility of patients coding rs3751143 to 
tuberculosis is most likely due to impaired P2X7-mediated killing of intracellular mycobacteria 
within macrophages [60, 71, 72], however other mechanisms such as impaired IL-1β release [73] or 
adaptive immune responses [74] cannot be excluded. The SNP rs3751143 has also been studied in 
multiple cohorts comprising patients with chronic lymphocytic leukemia (CLL) following initial 
observations that an increased frequency of rs3751143 may be associated with increased 
susceptibility to or prolonged survival in CLL [75, 76]. Neither association however was supported 
by additional studies [77-80] or by a meta-analysis of the combined studies [78]. Finally, an 
increased frequency of the mutant rs2230912 allele has been associated with mood disorders 
(bipolar or unipolar disorders) [81-85], however these findings have not been supported by other 
studies [86-88]. The rs2230912 SNP has only a minor effect on P2X7 function [14, 63] and it is 
currently difficult to reconcile how this SNP may be of physiological consequence in mood 
disorders. We have recently demonstrated however, that this SNP is in linkage disequilibrium with 
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three gain-of-function P2RX7 SNPs in a haplotype potentially leading to increased amounts of 
circulating IL-1β and altering mood states [63]. 
The association of P2RX7 SNPs with other diseases has been examined in a variety of other 
studies with many failing to find a significant association (Table 3). The majority of these studies 
have small sample sizes and thus lack sufficient statistical power to detect if a significant 
association exists. Future studies examining the association of P2RX7 SNPs with disease will 
benefit from the development of high-through genotyping, and the collection of large disease 
cohorts and appropriately matched controls. Moreover, future studies will need to consider the 
combined effect of multiple P2RX7 SNPs or haplotypes. Nevertheless further studies of P2X7 in 
relation to human health and disease are warranted based on observations in rodent models of 
disease, as well as with clinical samples obtained from humans. For example, P2X7 and its variants 
may play an important role in inflammatory and immune disorders such as rheumatoid arthritis. 
ATP induces significantly higher amounts of IL-1β release in blood samples obtained from 
rheumatoid arthritis patients compared to controls [89], while P2X7-deficient mice (Pfizer) have 
reduced severity and incidence of anti-collagen antibody-induced arthritis [90]. Additionally, an 
important role for P2X7 and its variants is suggested in relation to bone disorders. P2X7 is present 
on both human osteoclasts and osteoblasts [24, 28], while P2X7-deficient mice (Pfizer) display 
reduced bone formation and content [91]. A final example of the potential role of P2X7 and its 
variants is indicated in neurodegenerative disorders such as multiple sclerosis. P2X7 expression is 
expressed at higher amounts on spinal cord microglia from multiple sclerosis patients compared to 
controls [92], while P2X7-deficient mice (Glaxo-Smith-Kline) have reduced incidence of 
experimental autoimmune encephalomyelitis, a model of multiple sclerosis [93]. The role of P2X7 
in multiple sclerosis however, is confounded by an earlier study showing that experimental 
autoimmune encephalomyelitis is exacerbated in P2X7-deficient mice (Pfizer) [94]. 
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PATENTS REGARDING THE P2RX7 GENE & P2X7 VARIANTS 
 
A number of patents have been filed relating to either splice or polymorphic variants of the 
P2X7 receptor (Table 4). The majority of these patents outline claims for the detection of P2RX7 
variants in various disorders. Other patents mostly outline claims relating to P2RX7 gene 
expression. 
Several patents have been filed in relation to P2RX7 SNPs. Patent US7767398 [95] claims a 
method for diagnosing a mood (affective) disorder or susceptibility to a mood disorder in an 
individual encoding rs2230912 or a deletion of that allele. This patent follows an earlier patent 
(WO2004092384; [96]) of the same name undertaken by the same inventors. The claims of this 
earlier patent are broader including regions in the 5’ untranslated region, and exons 5 and 8 of 
P2RX7, as well as a number of other intronic and exonic P2XR7 SNPs. The association of 
rs2230912 with mood disorders was originally shown by the inventors [81, 83] and subsequently 
validated by others [84, 85], however as mentioned above others have failed to find an association 
between this SNP and mood disorders [86-88]. Nonetheless, our recent data indicates that 
rs2230912 lies in linkage disequilibrium with a gain-of-function haplotype [63] which may account 
for the discordance between the various genetic studies of P2RX7 and mood disorders [65]. In 
patent WO2010061246 [97], the inventors claim an in vitro method used to assess the sensitivity of 
subjects to chemotherapeutic or radiotherapeutic treatment of cancer. This assay relies on the 
detection of loss-of-function SNPs resulting in reduced function of the P2X7-elicited NALP3 
inflammasome pathway. This patent includes the loss-of-function P2RX7 SNPs, rs28360457, 
rs1653624, rs3751143 and rs2230911. This patent is based on recent data demonstrating a role for 
tumor-derived ATP and P2X7-mediated IL-1β release from dendritic cells in anti-tumor immune 
responses during chemotherapy. Treatment of human and murine cancer cells with a variety of 
chemotherapeutic agents or γ-irradiation induces the release of ATP into the extracellular 
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environment [74, 98, 99]. Moreover, in vitro and in vivo murine studies have shown that this ATP 
can activate P2X7 on dendritic cells to stimulate the NALP3 inflammasome and the subsequent 
release of biologically active IL-1β to generate interferon-γ producing anti-tumor CD8+ T-cells and 
effective anti-tumor adaptive immunity [74]. Of clinical significance, the P2RX7 SNP, rs3751143 
(Glu496Ala), which prevents ATP-induced IL-1β release [73], is associated with reduced metastatic 
disease-free survival rates in breast cancer patients treated with anthracyclines [74]. Patent 
US20090253585 [100] claims a genotyping method of predicting the susceptibility of a subject to 
develop a somatosensory disorder based on the identification of at least one haplotype or SNP from 
a very broad range of genes including P2RX7. This patent includes 16 P2RX7 SNPs (rs684201, 
rs685019, rs208288, rs17525809, rs208294, rs16950860, rs7958311, rs1718136, rs1718119, 
rs6489795, rs2230912, rs3751143, rs2230913, rs3751142, rs1621388 and rs1653625). Although a 
number of animal studies support a role for P2X7 in tactile sensation, nociception and pain [101-
104], evidence for a role for P2X7 in somatosensory disorders in humans including the association 
of loss- or gain-of-function P2XR7 SNPs is lacking. Patent US7205146 [105] claims a 12q23-qter 
nucleotide sequence (and an assay for its detection) which contains the P2RX7 SNP, rs7958311. 
Based on case-control association studies of North American and British cohorts [105], the 
inventors report a significant over-representation of the adenine-containing variant of rs7958311 
(coding for His at residue 270) in subjects with asthma, bronchial hyper-responsiveness or higher 
IgE amounts. The frequency of other P2RX7 SNPs in this study were not significantly different 
between controls and cases, and to the best of our knowledge this association study has not been 
published in a peer-reviewed journal. Patent WO2006136791 [106] claims a method to identify a 
P2XR7 haplotype containing rs169631 (intronic SNP; c>g) and rs3751143 in patients who are at 
risk of atherosclerosis and atherosclerosis-mediated diseases or conditions such as myocardial 
infarction. This genetic association is based on a cohort comprising 387 Swedish patients 
hospitalized due to myocardial infarction [106], however to the best of our knowledge this 
 13 
association study has not been published in a peer-reviewed journal. Patent EP1741722 [107] 
claims materials and methods for the identification of numerous P2RX7 SNPs including most of 
those listed in Table 1. This patent is broad in its application with no apparent claims to any specific 
disorders. 
Given the potential significance of various P2RX7 SNPs in various disorders it has also been 
of value to develop methods that can potentially identify subjects coding loss- or gain-of-function 
SNPs or haplotypes based on a phenotypic parameter such as P2X7-mediated pore formation [108, 
109]. Patents US7560243 [110] and US2009053204 [111] claim a flow cytometric-based assay to 
measure the relative P2X7 function (pore formation) in peripheral blood monocytes. This method 
has been extensively described [109, 112], and the measured pore formation correlates with the 
capacity of monocytes to release altered ratios of tumor necrosis factor-α and IL-10 [113], and with 
specific P2RX7 SNPs or haplotypes [114]. The potential clinical utility of this assay has been used 
to identify subjects at risk of virus-induced loss of asthma control [115]. This study however, did 
not report the P2RX7 genotype of the cohort. Thus, a direct correlation between clinical status or 
pore formation to P2RX7 genotype could not be ascertained. 
As an alternative to the detection of P2X7-mediated pore formation, the inventors of a series 
of patents WO2010000041 [116], WO2009033233 [117], WO2008043145 [118], WO2008043146 
[119], US7326415 [120] and WO2002057306 [121] claim the development of polyclonal and 
monoclonal antibodies (and related reagents) capable of binding to non-functional P2X7. Non-
functional receptors may result from non-synonymous SNPs in P2RX7 [122], however it is yet to be 
determined if the developed antibodies recognize all or only a sub-group of these receptors. The 
original antibody targeted an epitope within a loop adjacent to the extracellular ATP-binding site 
(residues 193-214) [123], and was found to bind non-functional P2X7 (including those arising from 
subjects carrying the rs3751143 mutant allele) but not to functional P2X7 [122]. Subsequently, it 
was shown that this antibody could bind to cells in malignant but not normal tissue, and allowed for 
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the differentiation of these two tissue states in melanoma, prostate cancer and breast cancer [124-
126]. 
Other patents relate to P2X7 isoforms. The inventors of patent US7767789 [127] claim 
materials and methods to detect P2X7J mRNA and protein in normal and malignant tissue. This 
claim relates to the inventors observations that P2X7J is over-expressed in certain epithelial 
malignancies and promotes an anti-apoptotic phenotype [55]. The inventors of patent 
WO2004090097 [128] claim a P2X7 isoform, HBMYP2X7v, containing a sequence of 1521 
nucleotides and encoding a polypeptide of 506 amino acids. In addition, the inventors claim 
methods relating to the detection of this variant in the diagnosis or treatment of a broad group of 
neurological and neurodegenerative disorders. However, it remains to be determined if this isoform 
leads to a product of functional significance or is of clinical relevance. 
Finally, a number of patents relate to the expression of the P2RX7 gene product. The 
inventors of patents US20090232893 [129], US20090227533 [130], US20090175827 [131] and 
US2009163434 [132] claim that miR-143, miR-34, miR-16 and miR-20 respectively modulate the 
expression of a large number of gene products, including P2X7, in a very broad group of disorders 
involving most of the systems within the body. Patent WO2008115387 [133] is more specific. The 
inventors of this patent claim the use of miR-150 and miR-186 as potential biomarkers in the 
management of uterine malignancies. This claim relates to data demonstrating that over-expression 
of these microRNAs in malignant uterine tissue down-regulates P2X7 and subsequently reduces 
ATP-induced apoptosis [51]. Conversely, patent WO2006024880 [134] claims the use of short 
inhibitory RNA (siRNA) to down-regulate P2X7 in patients from a very broad group of disorders 
including those of the neuronal, cardiovascular, inflammatory, cutaneous and renal systems. The 
potential utility of this application has been demonstrated by others using rats, where in vivo 
administration of siRNA to P2X7 impairs spinal nociceptive responses [135]. Finally, the inventors 
of WO2008142194 [136] claim a molecular-based method for measuring the P2RX7 gene product 
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in the diagnosis and prognosis of Huntington’s disease. This claim relates to data outlining evidence 
for increased P2X7 expression and function (Ca2+ flux and cell death) in neurons of mouse models 
of Huntington’s disease [137]. Evidence however for a role for P2X7 in Huntington’s disease in 
humans is lacking. 
 
CURRENT & FUTURE DEVELOPMENTS 
 
Splice and polymorphic variants of P2X7 are attracting considerable attention in human 
health and disease resulting in a number of related patents. Due to the prior publication of P2RX7 
and its isoforms and SNPs, the majority of patents relating to P2X7 claim the detection of P2RX7 
variants in specific or broadly specified disorders, rather than nucleotide sequences of P2RX7. This 
prior identification and publication of P2RX7 isoforms and SNPs independently of patents has 
greatly assisted and most likely expedited our understanding of P2X7 in human physiology and 
pathophysiology. Nevertheless the scientific merit and utility of current and future patents relating 
to the P2RX7 gene will need to be validated by larger sample sizes and examination by other 
investigators. It will also need to be determined if the relevance of such patents is restricted to 
specific racial groups or whether they have broader or universal application within the human 
population. In this regard, it still remains to be determined if many of the currently known P2RX7 
isoforms and SNPs exist in less-well studied human groups. Conversely, it remains to be 
determined if novel P2RX7 variants exist in such groups. Moreover, given the highly polymorphic 
nature of the P2XR7 gene and its receptor, future genetic association studies will need to include the 
analysis of P2RX7 haplotypes and the detailed phenotypic characterization of the encoded 
receptors. Included in this, is the further understanding of the mechanisms by which P2RX7 SNPs 
alter receptor expression and function including events downstream of P2X7 activation, and 
whether these SNPs have similar effects on P2RX7 splice isoforms particularly P2X7B. It will also 
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be of importance to determine the relative effectiveness of P2X7 therapeutics, currently under 
development or in clinical trials [9, 10], in relation to P2X7 isoforms and polymorphic variants. 
Finally, given that much of our understanding of P2X7 is inferred from rodent models of 
inflammatory, immune, bone, and neurological disorders, as well as pain, it will be important to 
directly establish a role for P2X7 in these and other human diseases to help develop and validate the 
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Fig. (1). Signaling events downstream of human P2X7 receptor activation. P2X7 is a trimeric 
ligand-gated cation channel (only one P2X7 subunit is shown). Activation of P2X7 by extracellular 
adenosine 5’-triphosphate (ATP) induces a number of downstream signaling events, as illustrated, 
in a variety of cell types. IL, interleukin; MMP-9, matrix metalloproteinase 9; PS, 
phosphatidylserine; RONS, reactive oxygen and nitrogen species. 
 
Fig. (2). Splice isoforms of the human P2X7 receptor. Top schematic representation shows the 
domains of the full-length human P2X7 receptor including the first (TM1) and second (TM2) 
transmembrane domains. Remaining schematic representations show the regions encoding the 
original, full-length human P2X7 receptor (P2X7A) and its splice isoforms (P2X7B to P2X7K). 
Numbered boxes and solid lines represent exons and alternate coding regions respectively. 
Additional exons, 1’ and N3, present in the introns (not shown) between exons 1 and 2, and exons 2 
and 3 respectively, are termed as originally described [55, 57]. The additional exon in P2X7G and 
P2X7H introduces a new start codon potentially leading to translation of a P2X7 protein lacking the 
first transmembrane domain. *To date P2X7K has been observed only in rodents. Schematic 
representations of the P2X7 isoforms are adapted from previous studies [53, 55]. 
 
Fig. (3). Characterized single nucleotide polymorphisms of the human P2RX7 gene. Schematic 
representations of the human (A) P2XR7 gene and (B) P2X7 subunit displaying single nucleotide 
polymorphisms. (A) Solid lines and numbered boxes represent introns (not to scale) and exons 
respectively. An additional exon, N3, in the intron between exons 2 and 3 is not shown. (B) Open 
circles, closed triangles and closed circles represent gain-, partial loss- and loss-of-function 
polymorphisms respectively; the open triangle represents a polymorphism with neutral effect on 
P2X7 function, but reduced sensitivity to inhibition by extracellular Ca2+. SNP rs35933842, which 
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leads to a null allele, is located in the intron between exons 1 and 2, and thus is not shown in the 
P2X7 subunit. Schematic representation of the human P2X7 subunit is adapted from a schematic of 
the murine P2X7 subunit of a previous study [138]. 
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Table 1. Characterized Single Nucleotide Polymorphisms of the Human P2RX7 Gene. 
 







rs35933842 gt>tt - Loss 0.008 [56] 
rs17525809 GTG>GCG Val76Ala Partial loss 0.062 [14, 63] 
rs28360445 CGG>TGG Arg117Trp Loss nd [14] 
rs28360447 GGA>AGA Gly150Arg Loss 0.018 [14, 63] 
rs208294 CAT>TAT His155Tyr Gain 0.439 [14, 58, 
63, 66, 
139] 
rs28360451 GAA>AAA Glu186Lys Loss nd [14] 
rs28360452 CTC>CCC Leu191Pro Loss nd [14] 
rs7958311 CAT>CGT His270Arg Gain 0.255 [63] 
rs7958316 CGT>CAT Arg276His Loss 0.020 [63] 
rs28360457 CGG>CAG Arg307Gln Loss 0.013 [67] 
rs1718119 GCT>ACT Ala348Thr Gain 0.400 [14, 58, 
63] 
rs2230911 ACT>AGT Thr357Ser Partial loss 0.083 [62] 
rs2230912 CAG>CGG Gln460Arg Partial loss 0.170 [63] 
rs3751143 GAG>GCG Glu496Ala Loss 0.175 [14, 58, 
59] 
rs2230913 CAC>CAG His521Gln Neutral2 0.020 [14] 
rs1653624 ATC>AAC Ile568Asn Loss 0.029 [14, 69] 
1Minor allele frequencies were previously described [63] except rs2230913 
(http://www.ncbi.nlm.nih.gov/projects/SNP); nd, not determined. 




Table 2. Functional Defects of the rs3751143 (Glu496Ala) Single Nucleotide Polymorphism 
 
Functional Defect Cell Types References 
Ba2+ (Ca2+), Rb+ (K+) flux Monocytes, B- and T-lymphocytes, 
erythrocytes 
[59, 73, 108, 140] 
Ethidium+, Yo-Pro-12+ 
uptake 
Macrophages, dendritic cells, 
Langerhans cells, monocytes, natural 
killer cells, B- and T-lymphocytes 
[18, 20, 59, 60, 71-73, 76, 
108, 109, 112-114, 122, 
141] 
CD23 shedding Dendritic cells, Langerhans cells [18, 20] 
CD62L shedding Monocytes, lymphocytes [73] 
IL-1β release Monocytes [73] 
IL-18 release Monocytes [141] 
TNF-α/IL-10 ratio Whole blood [113] 
Matrix metalloproteinase 9 
release 




Phospholipase D activation B-lymphocytes [143] 
Mycobacterial killing Macrophages [60, 71, 72] 
Toxoplasma killing Macrophages [61] 
Cell death Macrophages, B- and T-lymphocytes [59, 60, 71, 72, 76] 
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Fracture risk rs3751143, 
rs1653624 
rs28360457 Danish [145] 



















survival due to 
infection) 
 Korean [148] 
Toxoplasmosis rs1718119  North American, 
Brazilian 
[149] 
Tuberculosis rs2393799 (↓) rs3751143 Gambian [49] 
Tuberculosis rs2393799, 
rs1653624 (↓) 
rs3751143 Asian Indian [150] 
Tuberculosis  rs2393799, 
rs3751143 
Chinese Han [151] 
Tuberculosis  rs3751143 Peruvian [152] 
Tuberculosis rs3751143 rs2393799 Various3 [70] 
Tuberculosis rs3751143 rs2393799 Mexican 
Mestizo 
[153] 
Tuberculosis rs3751143 rs2393799 Russian 
Caucasian 
[154] 
Tuberculosis rs3751143  Australian 
Vietnamese 
[71] 
Tuberculosis rs3751143  Australian Asian [71] 
Tuberculosis rs3751143  Turkish children [155] 
Tuberculosis rs3751143  Punjabi [156] 
Inflammatory and cardiovascular disorders 
Ambulatory 
blood pressure 
rs591874 13 other British [157] 




Heart failure  rs3751143 Australian [159] 




































































 rs3751143 British [78] 
Multiple 
myeloma 












rs208294 Italian [166] 
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Psychiatric Disorders 
Anxiety rs1718119 rs2230912 
plus 10 other 
German [167] 














































 rs2230912 Swedish [88] 
Schizophrenia  rs2230912 
plus 8 other 
Danish [168] 
1Allele frequency significantly greater in cases compared to controls unless otherwise indicated (↓); 
comments in parenthesis indicate that the allele frequency was not significantly different between 
cases and controls, but correlated with specified clinical parameters. 
2Allele frequency not significantly different between cases and controls. 
3Meta-analysis of multiple studies (see corresponding reference for details). 
4Includes meta-analysis of multiple studies (see corresponding reference for details). 
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